FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1937496621> ?p ?o ?g. }

• W1937496621 endingPage "1952" @default.
• W1937496621 startingPage "1945" @default.
• W1937496621 abstract "PURPOSE The feasibility and pharmacokinetics of cyclosporine (CsA) delivered intraperitoneally (IP) have not been previously explored. We performed a pharmacokinetic study of IP CsA followed by a phase I dose-escalation trial of the combination of IP CsA and carboplatin in refractory ovarian cancer patients. PATIENTS AND METHODS A pilot study was performed of three patients who received 1, 10, and 20 mg/kg IP CsA alone. Subsequently, a phase I trial of 35 patients was performed between April 1990 and April 1993. Whole-blood and IP fluid CsA concentrations were measured at serial time points. The highest dose delivered IP was 34.6 mg CsA/kg in combination with carboplatin (250 mg/m2 or 300 mg/m2, depending on creatinine clearance), which was not dose-escalated. The area under the concentration-time curve (AUC) for CsA and half-life (T1/2) were calculated. Objective and serologic responses were noted, and toxicity was graded using the National Cancer Institute common toxicity criteria. RESULTS The feasibility of delivering IP CsA alone was established. We observed a 1,000:1 ratio between IP fluid and blood concentrations at 20 mg CsA/kg. Pharmacokinetic analysis confirmed that at 20 mg CsA/kg, there was an IP fluid-to-blood AUC ratio of 600:1 in favor of peritoneal exposure. At the highest dose delivered, 34.6 mg CsA/kg, the mean IP CsA levels of 1,110 micrograms/ mL were tolerated moderately well and the IP fluid-to-blood ratio of 1,000:1 was maintained. Blood and IP CsA concentrations were analyzed in the presence and absence of IP carboplatin. At 20 mg CsA/kg, there was no difference in either mean blood CsA levels (0.9 microgram/ mL) or mean IP CsA concentrations (1,000 micrograms/mL) obtained in the absence or presence of carboplatin. The most common toxicity in the phase I study was anemia, seen in 66% of patients. Common toxicities at the maximum CsA dose delivered (34.6 mg/kg) were anemia, leukopenia, thrombocytopenia, and hypertension. In this trial, three objective responses (two complete and one partial) were observed for a duration of 3 to 11 months. Control of platinum-resistant ascites was an important feature, noted in five of eight patients. CONCLUSION We have established the feasibility of delivering IP CsA up to doses of 34.6 mg/kg in conjunction with carboplatin, and the sustaining of IP fluid to blood ratios of 1,000:1. The IP administration of CsA resulted in a favorable ratio of exposure for the peritoneal cavity compared with systemic exposure, indicating a therapeutic advantage of this approach with a significant decrease in systemic toxicity. We recommend that 34.6 mg/ kg of IP CsA be tested as a phase II dose in combination with carboplatin in refractory ovarian cancer patients. This report provides the groundwork for future studies using IP CsA, both as a chemomodulator of platinum and of multidrug resistance." @default.
• W1937496621 created "2016-06-24" @default.
• W1937496621 creator A5016722881 @default.
• W1937496621 creator A5026827320 @default.
• W1937496621 creator A5041941916 @default.
• W1937496621 creator A5047386795 @default.
• W1937496621 creator A5055641686 @default.
• W1937496621 creator A5076812038 @default.
• W1937496621 creator A5080149644 @default.
• W1937496621 creator A5081276373 @default.
• W1937496621 date "1997-05-01" @default.
• W1937496621 modified "2023-09-28" @default.
• W1937496621 title "Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients." @default.
• W1937496621 cites W1243345400 @default.
• W1937496621 cites W1512121436 @default.
• W1937496621 cites W1534946515 @default.
• W1937496621 cites W1757352256 @default.
• W1937496621 cites W1816122400 @default.
• W1937496621 cites W1927327874 @default.
• W1937496621 cites W1945760023 @default.
• W1937496621 cites W1949997781 @default.
• W1937496621 cites W1958840615 @default.
• W1937496621 cites W2001350377 @default.
• W1937496621 cites W2007630715 @default.
• W1937496621 cites W2008523006 @default.
• W1937496621 cites W2011120404 @default.
• W1937496621 cites W2014114494 @default.
• W1937496621 cites W2034245187 @default.
• W1937496621 cites W2061048046 @default.
• W1937496621 cites W2084644469 @default.
• W1937496621 cites W2088419541 @default.
• W1937496621 cites W2106436131 @default.
• W1937496621 cites W2116771628 @default.
• W1937496621 cites W2117729836 @default.
• W1937496621 cites W2146195154 @default.
• W1937496621 cites W2157548366 @default.
• W1937496621 cites W2234488796 @default.
• W1937496621 cites W2417047339 @default.
• W1937496621 cites W2464381639 @default.
• W1937496621 cites W2475522389 @default.
• W1937496621 cites W2483966432 @default.
• W1937496621 cites W2484144334 @default.
• W1937496621 doi "https://doi.org/10.1200/jco.1997.15.5.1945" @default.
• W1937496621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9164206" @default.
• W1937496621 hasPublicationYear "1997" @default.
• W1937496621 type Work @default.
• W1937496621 sameAs 1937496621 @default.
• W1937496621 citedByCount "12" @default.
• W1937496621 countsByYear W19374966212014 @default.
• W1937496621 countsByYear W19374966212015 @default.
• W1937496621 countsByYear W19374966212017 @default.
• W1937496621 countsByYear W19374966212022 @default.
• W1937496621 crossrefType "journal-article" @default.
• W1937496621 hasAuthorship W1937496621A5016722881 @default.
• W1937496621 hasAuthorship W1937496621A5026827320 @default.
• W1937496621 hasAuthorship W1937496621A5041941916 @default.
• W1937496621 hasAuthorship W1937496621A5047386795 @default.
• W1937496621 hasAuthorship W1937496621A5055641686 @default.
• W1937496621 hasAuthorship W1937496621A5076812038 @default.
• W1937496621 hasAuthorship W1937496621A5080149644 @default.
• W1937496621 hasAuthorship W1937496621A5081276373 @default.
• W1937496621 hasConcept C112705442 @default.
• W1937496621 hasConcept C121608353 @default.
• W1937496621 hasConcept C126322002 @default.
• W1937496621 hasConcept C126894567 @default.
• W1937496621 hasConcept C2776694085 @default.
• W1937496621 hasConcept C2778239845 @default.
• W1937496621 hasConcept C2780427987 @default.
• W1937496621 hasConcept C2781451048 @default.
• W1937496621 hasConcept C29730261 @default.
• W1937496621 hasConcept C71924100 @default.
• W1937496621 hasConcept C76318530 @default.
• W1937496621 hasConcept C98274493 @default.
• W1937496621 hasConceptScore W1937496621C112705442 @default.
• W1937496621 hasConceptScore W1937496621C121608353 @default.
• W1937496621 hasConceptScore W1937496621C126322002 @default.
• W1937496621 hasConceptScore W1937496621C126894567 @default.
• W1937496621 hasConceptScore W1937496621C2776694085 @default.
• W1937496621 hasConceptScore W1937496621C2778239845 @default.
• W1937496621 hasConceptScore W1937496621C2780427987 @default.
• W1937496621 hasConceptScore W1937496621C2781451048 @default.
• W1937496621 hasConceptScore W1937496621C29730261 @default.
• W1937496621 hasConceptScore W1937496621C71924100 @default.
• W1937496621 hasConceptScore W1937496621C76318530 @default.
• W1937496621 hasConceptScore W1937496621C98274493 @default.
• W1937496621 hasIssue "5" @default.
• W1937496621 hasLocation W19374966211 @default.
• W1937496621 hasLocation W19374966212 @default.
• W1937496621 hasOpenAccess W1937496621 @default.
• W1937496621 hasPrimaryLocation W19374966211 @default.
• W1937496621 hasRelatedWork W1489103099 @default.
• W1937496621 hasRelatedWork W2034009362 @default.
• W1937496621 hasRelatedWork W2100301731 @default.
• W1937496621 hasRelatedWork W2311734504 @default.
• W1937496621 hasRelatedWork W2321468987 @default.
• W1937496621 hasRelatedWork W2330726202 @default.
• W1937496621 hasRelatedWork W2365498864 @default.
• W1937496621 hasRelatedWork W2443311901 @default.

• next